Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 24 of 65 · 3103 articles
This trial tests a new oral drug, SAR441566, as a potential treatment for moderate-to-severe ulcerative colitis. Results could affect future treatment options if the drug is effective and safe.
This trial is testing risankizumab in children with moderate-to-severe Crohn’s disease to learn how the drug behaves in kids, whether it’s safe, and whether it reduces disease activity — information that could expand...
This trial tests a new oral drug for moderate to severe ulcerative colitis with a short (12-week) primary endpoint; people with active UC may be interested in emerging treatment options and clinical trial opportunities.
This trial tests a safe, non-drug supplement (GlcNAc) as a precision-medicine approach for Crohn's disease based on a genetic variant that affects glycosylation. If successful, it could offer a new, well-tolerated...
Ulcerative colitis changes the colonic environment in ways that can make current mesalazine formulations release unpredictably. New delivery approaches aimed at stabilising drug interfaces could lead to more consistent...
This preclinical study suggests probiotic-derived extracellular vesicles may reduce intestinal inflammation and restore barrier function via PPARγ signaling and changes to the gut microbiome—an early step toward...
This analysis directly addresses treatments commonly used for perianal fistulizing Crohn’s disease and compares biologic anti-TNF drugs with emerging mesenchymal stem cell therapy, information that could affect treatment...
This study suggests a new preclinical approach to help the gut lining heal in ulcerative colitis by targeting macrophage metabolism (myeloid AMPK) rather than directly treating epithelial cells. That could matter for...
This paper describes a novel nanozyme that reduced oxidative stress and inflammation in preclinical models of colitis and enteropathic arthritis — a possible future therapeutic approach that targets ROS in inflamed gut...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Immunity, inflammation...
The ENS–gut microbiota field intersects with IBD research through shared mechanisms (neuroinflammation, neuro‑immune interactions) and potential microbiota‑based therapies, so mapping trends helps patients and clinicians...
The study describes a new berberine-containing nanocomplex that reduced inflammation and improved gut barrier function in cell, mouse, and organoid models of ulcerative colitis, suggesting a potential new direction for...
Patient-centered measures help clinics track and improve care experiences important to people with IBD. A validated patient-developed PREM could better reflect patient priorities and support quality improvement in UK IBD...
Wearable-derived digital biomarkers aim to detect flares earlier and reduce reliance on questionnaires; patients' acceptance is essential for real-world use. High reported willingness suggests patient-centered...
Trials testing intestinal ultrasound–guided treat-to-target strategies and late-stage therapies could change how Crohn’s disease is monitored and treated if they show improved outcomes.
This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...
Knowing a patient’s estimated infliximab clearance before starting rescue therapy for acute severe ulcerative colitis could help identify who may need higher or intensified induction dosing and who might be at greater...
Microplastics are a widespread environmental exposure that this review links to biological changes relevant to IBD — intestinal barrier damage, microbiome shifts, and immune activation — so patients and clinicians may...
The study suggests there may be stage-specific differences in mucosal IgA and IgG plasma cell patterns in UC, which could help researchers understand mucosal immunity changes across active disease, quiescence, and...
The study suggests FMT can clear mucosal adherent‑invasive E. coli (AIEC) in some people with Crohn’s disease and alters mucosal microbiome features linked to inflammation, which could be relevant to microbiome‑targeted...
This trial tests whether oral vancomycin can help children with atypical ulcerative colitis or PSC-associated colitis and whether changes in gut bacteria or metabolites explain response. If effective and safe, it could...
Phase 3 trials test whether a new oral therapy can induce remission in people with moderate-to-severe ulcerative colitis who have not responded to or cannot tolerate existing treatments. If positive, results could add...
People with IBD who are treated with anti‑TNFα drugs commonly develop inflammatory or infectious skin problems. This study aims to clarify whether Staphylococcus aureus is more abundant in those lesions and whether its...
Knowing which treatment target (symptom control alone versus adding endoscopic and histological remission) leads to better long-term outcomes could change how aggressively clinicians treat ulcerative colitis and what...
This trial studies adalimumab safety and pediatric dosing in children with moderate–severe Crohn's disease, which is directly relevant to families and clinicians considering anti-TNF therapy for pediatric IBD.
Phase 3 trials test whether a new drug is effective and safe enough to be considered for clinical use. ABX464 is being evaluated as a potential new oral treatment for people with moderate-to-severe ulcerative colitis who...
Intestinal ultrasound can assess IBD inflammation without radiation but interpretation varies by operator. Developing AI tools to measure bowel wall thickness and other features could standardize and speed image...
If confirmed in clinical trials, targeting NAD+ metabolism or removing senescent immune cells could become new approaches to treat ulcerative colitis, especially for patients with severe disease or who do not respond to...
The intestinal barrier changes in inflammation and can alter how oral nanocarriers interact with mucus and epithelium; understanding this is important for designing delivery systems that achieve local therapeutic benefit...
Many people with IBD remain symptomatic even when tests show little or no inflammation; recognising these persistent symptoms as a separate treatment target could improve quality of life. This reframes care to address...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Computer Methods in...
Patients and clinicians want to know whether tofacitinib raises blood clotting or platelet activation risk in ulcerative colitis, because similar safety concerns were reported in other diseases.
ITB can closely mimic Crohn’s disease, so this study is relevant because it describes diagnostic test yields and illustrates that targeted TB testing and therapeutic trials of antituberculosis treatment can help...
Researchers and clinicians interested in cross-disease host–microbe interactions may find that an IBD–CRC shared microbial/host signature could have prognostic importance beyond the gut, here in bladder cancer.
The study identifies blood gene-expression patterns linked to response to TNF-alpha inhibitors and highlights overlap between psoriasis and IBD, which could point to shared biomarkers or mechanisms relevant to treatment...
The study raises the possibility that perinatal exposure to nanoplastics could have lasting, sex-specific effects on gut health and make adult offspring more susceptible to intestinal inflammation. This may be relevant...
The study explores using coordinated, longitudinal multi-omic profiles to better detect true responses to anti-TNF therapy and to inform personalized treatment selection for people with IBD.
This study shows that sodium butyrate, a metabolite produced by gut bacteria, changed brain imaging measures and reduced inflammation in mice with experimental IBD, supporting the idea that gut-derived compounds can...
Fatigue affects more than half of people with IBD and is a leading cause of impaired quality of life. A machine-learning approach that identifies distinct patient-level patterns may help researchers and clinicians...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from Gastroenterology &...
The study suggests a probiotic–ω‑3 combination (a synbiotic) might boost the anti‑inflammatory, pro‑resolving effects of ω‑3s in colonic tissue—potentially relevant for people with ulcerative colitis looking for adjunct...
IL-22 links microbial metabolites to epithelial repair and inflammation; clarifying these pathways could inform future therapies or dietary/microbiome approaches to promote mucosal healing without worsening inflammation.
This review highlights a new, non-live microbiome-based therapy approach (probiotic-derived EVs) that could in future modulate gut immunity and barrier function without using live microbes. For people with IBD, such...
Real-world 52-week data suggest mirikizumab can produce meaningful remission and reasonable drug persistence in patients with treatment-experienced ulcerative colitis. This is especially relevant for people who have not...
Simple, routinely measured nutritional scores were associated with early (14-week) remission on vedolizumab in patients with moderate-to-severe UC, which could help identify patients more likely to respond early to this...
Patients with hidradenitis suppurativa have higher baseline IBD risk, and IL-17 inhibitors are effective HS treatments. People with Crohn’s disease or ulcerative colitis (or those at risk) may worry whether these drugs...
The study links a specific gut microbe and its metabolite to reduced inflammation and improved barrier function in ulcerative colitis models and cohort comparisons, suggesting a potential new microbiome-targeted therapy...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Biomarkers. The original article is from Biochemia medica.
